2:58 PM
 | 
Apr 17, 2019
 |  BC Extra  |  Preclinical News

Salk study unveils LIF's mechanism in form of pancreatic cancer

A new study from Salk Institute for Biological Studies pinpoints new mechanistic details about how LIF promotes pancreatic cancer, providing preclinical support for Northern Biologics' lead candidate.

In a Nature paper published Wednesday, Salk's Tony Hunter and colleagues showed that LIF is secreted by pancreatic stellate cells (PSCs) to drive pancreatic ductal adenocarcinoma (PDAC) progression and chemoresistance.

Hunter is professor of molecular and cell biology at Salk. Northern Biologics Inc. (Toronto, Ontario) started a Phase I trial of its anti-LIF...

Read the full 384 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >